

Participant
Rating



4.5 of 5



ABCT

Accelerator for Biosciences in Connecticut

IMPACT REPORT

2018 – 2022

AN INITIATIVE OF:

ctnext

A PROGRAM OF:

FIRSTXFOUNDER

www.abct.co

Info-abct@firstxfounder.com

TABLE OF CONTENTS



ABCT

CT poised to be a Bio Hub	3
Who We Are	4
Mobilizing CT Life Sciences	5
Connecting the Eco System	6
Technology & Founder Diversity	7
Pipeline to fuel CT growth	8
Alum Success	9
Testimonials	10

CT Poised to be a hub



ABCT

Midway between NY & Boston bio hubs

Highly educated workforce

MNC's

Boehringer Ingelheim, Pfizer

Medtronic, Former: Bayer, BMS

CI top 3 bio seed investor in US



Accelerator for Biosciences in Connecticut, ABCT is the

- * only **competitive-entry** accelerator program offering
- * a six-month free, personalized founder education
- * for **first time founders** of any development stage
- * in 4 years \$101M raised, 200 jobs created by 46 ventures




ABCT focuses on unlocking the unknown by addressing individual venture needs led by **entrepreneur coaches**, delivering a **structured curriculum** with expert mentors to craft unique, educational experiences crucial to the development of successful ventures.



Founded 2017

Accelerator for Biosciences in Connecticut 2018-2022



*One venture participated twice with different companies

University Affiliations



ABCT is helping to connect the Life Science Eco System in Connecticut



ABCT

Connections


Mentors Connections per Venture by Cohort :

- 2018 → 3.0
- 2019 → 6.0
- 2020 → 10.7
- 2021 → 12.6
- 2022 → 14

2022 vs. 2021 Education Events :

- + 12 bootcamp workshop;
- + 5 webinars;
- + 4 Coach planning meetings

Events



Corporate Supporters



**WILSON
SONSINI**

MARCUM
ACCOUNTANTS ▲ ADVISORS

wiggin(x)
by Wiggin and Dana LLP


JPMORGAN CHASE & Co.

ATOSTEK


ABCT is building a Diverse Technology & Founder Eco System Pipeline



Technology Type



Venture Leadership



ABCT building a Pipeline to fuel CT growth



ABCT

Cohort	2022	2021	2020	2019	2018
Revenue Generating			 		
Non-dilutive funding		 	 	 	
Seed / Series A		 	 	 	
Series B +					
Exit					

ALUM SUCCESS: 1st Exit, Multiple Investments



Allomek Acquired

MEK inhibitor acquired by
Pasithea



October 12, 2022
Pasithea
Therapeutics
(KTTA) acquires
Allomek



Closes Series A

High Throughput
Discovery platform



Summer, 2022



Closes Seed



Neurostim
Device to regain
Movement

Spring, 2022



Closes Series A1

Microbiome
Research
& Discovery
platform



Summer, 2022



“I am very thankful to be exposed to years of accumulated wisdom and the generosity from coaches mentors and previous program participants.

The ABCT team is outstanding and incredibly supportive.”

**Smart Cardio-Oncology Health -
Olga Toro-Salazar, MD**



“Excellent networking both within and outside the cohort.”

**OHM Dynamics
- David Pritchard**



“Great exposure to the entrepreneurial process and excellent Networking and exposure to potential investors.”

**EMpedicsMSK Curbsider
- Samuel Oduwole,MD**



We Help Build
Emergent Companies

AN INITIATIVE OF:

ctnext

A PROGRAM OF:

FIRSTXFOUNDER

www.abct.co
Info-abct@firstxfounder.com